The Ethics of Excluding Pregnant People from GLP-1 Drug Research
Systematic exclusion of pregnant individuals from GLP-1 research creates dangerous evidence gaps that a reproductive justice framework could address.
Quick Facts
What This Study Found
The protectionist exclusion of pregnant people from GLP-1 research creates evidence gaps that may cause more harm than inclusive research would.
Key Numbers
No clinical data presented; this is an ethical and policy analysis.
How They Did This
Bioethics analysis applying the protectionist ethic framework and reproductive justice theory to GLP-1 RA research.
Why This Research Matters
Without pregnancy data, clinicians must make decisions about GLP-1 drugs in pregnant patients based on absence of evidence rather than evidence of safety.
The Bigger Picture
This reflects a broader movement to include pregnant people in clinical research so evidence-based decisions can replace precautionary guesswork.
What This Study Doesn't Tell Us
Theoretical/ethical analysis — does not provide new clinical data on GLP-1 safety in pregnancy.
Questions This Raises
- ?How can GLP-1 pregnancy trials be designed to minimize risk while generating needed data?
- ?What registry data exists on inadvertent GLP-1 exposure during pregnancy?
Trust & Context
- Key Stat:
- Evidence gap Systematic exclusion of pregnant people from GLP-1 trials leaves clinicians without safety data
- Evidence Grade:
- Bioethics commentary — provides ethical framework analysis, not clinical evidence.
- Study Age:
- Published in 2025, timely given the massive expansion of GLP-1 use among women of reproductive age.
- Original Title:
- How Bioethics and Reproductive Justice Ought to Inform Glucagon-Like Peptide-1 Receptor Agonists, Research, and Pregnancy.
- Published In:
- Obesity reviews : an official journal of the International Association for the Study of Obesity, e70047 (2025)
- Authors:
- Pondugula, Nishita, Merriam, Audrey A
- Database ID:
- RPEP-13078
Evidence Hierarchy
Frequently Asked Questions
Is it safe to take GLP-1 drugs during pregnancy?
We don't know — pregnant people have been excluded from clinical trials, creating a major evidence gap. Current guidelines recommend stopping GLP-1 drugs before conception.
Why are pregnant people excluded from drug studies?
A protectionist ethic aims to shield fetuses from research risk, but this creates paradoxical harm by leaving clinicians without evidence to guide treatment.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13078APA
Pondugula, Nishita; Merriam, Audrey A. (2025). How Bioethics and Reproductive Justice Ought to Inform Glucagon-Like Peptide-1 Receptor Agonists, Research, and Pregnancy.. Obesity reviews : an official journal of the International Association for the Study of Obesity, e70047. https://doi.org/10.1111/obr.70047
MLA
Pondugula, Nishita, et al. "How Bioethics and Reproductive Justice Ought to Inform Glucagon-Like Peptide-1 Receptor Agonists, Research, and Pregnancy.." Obesity reviews : an official journal of the International Association for the Study of Obesity, 2025. https://doi.org/10.1111/obr.70047
RethinkPeptides
RethinkPeptides Research Database. "How Bioethics and Reproductive Justice Ought to Inform Gluca..." RPEP-13078. Retrieved from https://rethinkpeptides.com/research/pondugula-2025-how-bioethics-and-reproductive
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.